NCT07084038Active, not recruiting
Effect of Glycosuria on Urinary Protein in Patients With Chronic Kidney Disease Treated With SGLT2 Inhibitors
Effect of Glycosuria on Urinary Protein in Patients With Chronic Kidney Disease Treated With SGLT2 Inhibitor
Source: ClinicalTrials.gov · Last updated 3 Sept 2025
Brief summary (registry, in English)
This trial aims to investigate the correlation between glycosuria levels and urinary protein in chronic kidney disease patients treated with Sodium-Glucose Transporter 2 Inhibitors(SGLT2i), and to explore whether glycosuria can reflect the therapeutic response to SGLT2i in these patients. Through this study, the investigators hope to provide some clinical references for optimizing SGLT2i dosing strategies.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 22 Jul 2025
- Start date
- 1 Jul 2024
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Yuanjun Yang
- Diseases
- Chronic kidney disease
- NCT number
- NCT07084038
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 Jul 2024 to the primary completion date, 30 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of corticosteroids or having an indication for corticosteroid therapy within the past 6 months.
- Receipt of immunosuppressive therapy or having an indication for immunosuppressive therapy within the past 6 months.
Other illness
- Discontinuation of SGLT2i during the follow-up period. History of symptomatic hypotension (systolic blood pressure\<90 mmHg) without antihypertensive medication, or current hypotensive episode at screening.
- History of intolerance to SGLT2 inhibitors. History of ketoacidosis within the past 5 years.
Lab values
- Unstable renal function (e.g., acute kidney injury or rapidly progressive glomerulonephritis with a \>50% decline in eGFR within 3 months prior to screening).
Who the study is looking for
- Age ≥18 years. Patients with a confirmed diagnosis of chronic kidney disease (CKD). Currently receiving stable, standard-dose SGLT2i therapy at screening. Proteinuria ≥0.15 g/24 h (or urine protein-to-creatinine ratio \[UPCR\] ≥440 mg/g or urine albumin-to-creatinine ratio \[UACR\] ≥300 mg/g) at screening.
- Estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73m² calculated by the CKD-EPI creatinine equation at screening.
- Willing and able to provide written informed consent.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese PLA General Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.